![Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hyd…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fcas-image%2Fthumb-webp%2F363518-cyclopropaneacetic-acid-1-1r-1-3-1e-2-7-chloro-2-quinolinyl-ethenyl-phenyl-3-2-1-hydroxy-1-methylethyl-phenyl-propyl-thio-methyl-sodium-salt-1-1.webp&w=3840&q=75)
CAS 151767-02-1
:Ácido ciclopropanoacético, 1-[[[(1R)-1-[3-[(1E)-2-(7-cloro-2-quinolinil)etenil]fenil]-3-[2-(1-hidroxi-1-metiletil)fenil]propil]tio]metil]-, sal de sódio (1:1)
Descrição:
Ácido ciclopropanoacético, 1-[[[(1R)-1-[3-[(1E)-2-(7-cloro-2-quinolinil)etenil]fenil]-3-[2-(1-hidroxi-1-metiletil)fenil]propil]tio]metil]-, sal de sódio (1:1) é um composto orgânico complexo caracterizado por suas características estruturais únicas, incluindo um anel de ciclopropano e vários grupos funcionais que contribuem à sua reatividade química e atividade biológica. Como sal de sódio, é provável que apresente maior solubilidade em água em comparação com sua forma ácida, o que pode aumentar sua biodisponibilidade em aplicações farmacêuticas. A presença de um grupo quinolina sugere propriedades farmacológicas potenciais, possivelmente incluindo atividades antimicrobianas ou anticancerígenas. A ligação tioéter do composto também pode influenciar sua estabilidade e reatividade. Sua estrutura intrincada indica que pode interagir com alvos biológicos de maneira específica, tornando-o de interesse na química medicinal. No geral, este composto exemplifica a complexidade frequentemente encontrada em moléculas semelhantes a fármacos, combinando múltiplos grupos funcionais que podem conferir diversas propriedades químicas e biológicas.
Fórmula:C35H36ClNO3S·Na
InChI:InChI=1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/b15-10+;/t32-;/m1./s1
Chave InChI:InChIKey=ZMFQNQCXWQXCFO-HKHDRNBDSA-N
SMILES:C(S[C@H](CCC1=C(C(C)(C)O)C=CC=C1)C2=CC(/C=C/C3=NC4=C(C=C3)C=CC(Cl)=C4)=CC=C2)C5(CC(O)=O)CC5.[Na]
Sinónimos:- 1-[[[(R)-1-[3-[(E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid sodium salt
- 2-[1-[[1-[3-[2-[(7-Chloro-2-Quinolyl)]Vinyl]Phenyl]-3-[2-(1-Hydroxy-1-Methyl-Ethyl)Phenyl]-Propyl]Sulfanylmethyl]Cyclopropyl]Acetic Acid Sodium Salt
- 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid sodium salt
- Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, monosodium salt
- Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1)
- Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, monosodium salt, [R-(E)]-
- Kokast
- Methyl-[E]-(+)-1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)-ethenyl]phenyl]-3-[2-(1-hydroxyl-1-methylethyl)phenyl]propyl]mercapto]methyl]cyclopropane acetic acid sodium
- Mk-476
- Momazol
- Montair
- Montelukast Sodium Amorphous
- Montelukast monosodium salt
- Montikast
- Shantroz
- Singulair
- Sodium 2-[1-[[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetate
- Sodium montelukast
- sodium (1-{[(1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl)sulfanyl]methyl}cyclopropyl)acetate
- sodium {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetate
- sodium(R,E)-2-(1-(1-(3-(-(7-chloroqulnolln-2-yl)-3-(2-(2 hydroxypropan-2-yl)phenyl)propylthio)cyclopropyl)acetate
- Ver mais sinónimos
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
19 produtos.
MONTELUKAST FOR PEAK IDENTIFICATION CRS
CAS:<p>MONTELUKAST FOR PEAK IDENTIFICATION CRS</p>Fórmula:C35H35ClNNaO3SPeso molecular:608.1651MONTELUKAST SODIUM CRS
CAS:<p>MONTELUKAST SODIUM CRS</p>Fórmula:C35H35ClNNaO3SPeso molecular:608.1651Montelukast Sodium
CAS:Drugs containing a quinoline or isoquinoline ring-system (whether or not hydrogenated) not further fusedFórmula:C35H35ClNO3S·NaCor e Forma:White Off-White PowderPeso molecular:607.19239Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1)
CAS:Fórmula:C35H35ClNNaO3SPureza:98%Cor e Forma:SolidPeso molecular:608.1651Montelukast sodium salt
CAS:Fórmula:C35H35NO3ClNaSPureza:≥ 99.0%Cor e Forma:White to almost white powder or crystalsPeso molecular:608.17057Montelukast Sodium Salt
CAS:Fórmula:C35H35ClNO3S·NaCor e Forma:Pale Yellow SolidPeso molecular:585.18 22.99Montelukast sodium
CAS:Produto ControladoFórmula:C35H35ClNO3S·NaCor e Forma:NeatPeso molecular:608.17Montelukast Sodium
CAS:Produto ControladoFórmula:C35H35ClNO3S·NaCor e Forma:NeatPeso molecular:608.17Montelukast Sodium
CAS:Fórmula:C35H35ClNNaO3SPureza:>98.0%(T)(HPLC)Cor e Forma:White to Almost white powder to crystalPeso molecular:608.17Montelukast sodium
CAS:<p>Montelukast sodium (MK0476), an oral leukotriene antagonist for asthma, can cause rare liver injury.</p>Fórmula:C35H35ClNNaO3SPureza:99.14% - 99.89%Cor e Forma:White To Off-White Crystalline PowderPeso molecular:608.17Montelukast Sodium Salt
CAS:Produto Controlado<p>Applications A selective leukotriene D4-receptor antagonist. Used as an antiasthmatic.<br>References Labelle, M., et al.: Bioorg. Med. Chem. Lett., 5, 283 (1995), Jones, T.R., et al.: Can. J. Physiol. Pharmacol., 73, 191 (1995), Markham, A. and Faulds, D.: Drugs, 56, 251 (1998)<br></p>Fórmula:C35H35ClNO3S·NaCor e Forma:White To Light YellowPeso molecular:608.17Montelukast sodium salt - Bio-X ™
CAS:<p>Montelukast is a leukotriene receptor antagonist that blocks the binding of leukotrienes to their receptors. It is used for the treatment of chronic cough, as well as for the relief of symptoms of seasonal and perennial allergic rhinitis. Montelukast binds to leukotriene receptors on cells in the airways, preventing them from attaching to leukotrienes and triggering an inflammatory response. This drug has been shown to be effective in controlling asthma symptoms by reducing bronchial hyperresponsiveness and relieving respiratory obstruction due to inflammation. Montelukast also has anti-inflammatory properties, which are thought to be due to its ability to inhibit production of pro-inflammatory cytokines such as IL-6.</p>Fórmula:C35H36ClNO3S•NaPureza:Min. 95%Cor e Forma:PowderPeso molecular:608.17 g/molMontelukast sodium
CAS:<p>Montelukast sodium is a leukotriene receptor antagonist that blocks the binding of leukotrienes to their receptors. It is used for the treatment of chronic cough, as well as for the relief of symptoms of seasonal and perennial allergic rhinitis. Montelukast sodium binds to leukotriene receptors on cells in the airways, preventing them from attaching to leukotrienes and triggering an inflammatory response. This drug has been shown to be effective in controlling asthma symptoms by reducing bronchial hyperresponsiveness and relieving respiratory obstruction due to inflammation. Montelukast sodium also has anti-inflammatory properties, which are thought to be due to its ability to inhibit production of pro-inflammatory cytokines such as IL-6.</p>Fórmula:C35H35ClNNaO3SPureza:Min. 95%Cor e Forma:PowderPeso molecular:608.17 g/molMontelukast-d6 Sodium Salt
CAS:Produto ControladoFórmula:C35H29D6ClNNaO3SCor e Forma:NeatPeso molecular:614.2
![Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hyd…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA003S60.jpg&w=3840&q=75)
